This article is more than 5 years old. Information may no longer be current.
Allergan pharmaceutical sales up 15% over third quarter of 2003
Click Here to Manage Email Alerts
IRVINE, Calif. — Allergan’s net sales were $510 million during the third quarter of 2004, with an increase of 15% in pharmaceutical sales over the third quarter of 2003, the company announced in a press release.
During the third quarter, eye care pharmaceutical sales rose to $285.4 million from $252.8 million in the same quarter 1 year ago, the company announced. The strongest sales were reported for glaucoma medications Alphagan P (brimonidine with Purite preservative), Alphagan (brimonidine) and Lumigan (bimatoprost). Lumigan showed the largest jump in sales, from $46.9 million in the third quarter of 2003 to $60.3 million in the third quarter of 2004. Other leading eye care medications included Restasis (cyclosporine) for dry eye.
Botox (botulinum toxin) posted sales of $174.6 million during the third quarter of 2004, an increase of $34.7 million from the same quarter in 2003.
Other highlights from the quarter included the receipt of an “approvable” letter from the Food and Drug Administration for a fixed combination of bimatoprost and timolol, according to the press release.